Home

Édition Agrafe Mathématicien kevin harrington icr jupe Compter les insectes Soldat

Professor Kevin Harrington - The Institute of Cancer Research, London
Professor Kevin Harrington - The Institute of Cancer Research, London

The ICR on Twitter: "We were delighted to welcome @JonAshworth (MP &  Shadow Health Secretary) to visit us today with @CRUK_Policy to meet  Professor Kevin Harrington and team. Jon saw some of
The ICR on Twitter: "We were delighted to welcome @JonAshworth (MP & Shadow Health Secretary) to visit us today with @CRUK_Policy to meet Professor Kevin Harrington and team. Jon saw some of

Radiotherapy supercharges cancer-targeting viruses to treat deadly skin  cancer - The Institute of Cancer Research, London
Radiotherapy supercharges cancer-targeting viruses to treat deadly skin cancer - The Institute of Cancer Research, London

Professor Kevin Harrington to star in BBC2's Trust me, I'm a Doctor - The  Institute of Cancer Research, London
Professor Kevin Harrington to star in BBC2's Trust me, I'm a Doctor - The Institute of Cancer Research, London

Kevin Harrington - Reader in Biological Cancer Therapies - Institute of  Cancer Research | LinkedIn
Kevin Harrington - Reader in Biological Cancer Therapies - Institute of Cancer Research | LinkedIn

ICR calls for improved biomarker cancer tests to help personalise treatment  - PMLiVE
ICR calls for improved biomarker cancer tests to help personalise treatment - PMLiVE

ICR researchers named among world's most influential scientists - The  Institute of Cancer Research, London
ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London

Harnessing the power of radiotherapy | TRM CancerBRC
Harnessing the power of radiotherapy | TRM CancerBRC

Professor Kevin Harrington | The Royal Marsden
Professor Kevin Harrington | The Royal Marsden

The ICR on Twitter: "Today, Prof. Kevin Harrington (ICR/@cancerBRC) will  present on a trial of RP2, a first-in-class, enhanced potency oncolytic HSV  expressing an anti-CTLA-4 antibody as a single agent and combined
The ICR on Twitter: "Today, Prof. Kevin Harrington (ICR/@cancerBRC) will present on a trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined

The ICR on Twitter: "🧬 The ICR's Professor Kevin Harrington and his team  are using viral #Immunotherapy to harness the body's immune system to kill  cancer. See their research with T-VEC, a
The ICR on Twitter: "🧬 The ICR's Professor Kevin Harrington and his team are using viral #Immunotherapy to harness the body's immune system to kill cancer. See their research with T-VEC, a

Prof Kevin Harrington | Events | Imperial College London
Prof Kevin Harrington | Events | Imperial College London

Professor Kevin Harrington - YouTube
Professor Kevin Harrington - YouTube

The ICR on Twitter: "Watch Professor Kevin Harrington on @BBCLondonNews as  he shares more on how a modified version of the herpes virus could offer  hope for some people with advanced #Cancer.
The ICR on Twitter: "Watch Professor Kevin Harrington on @BBCLondonNews as he shares more on how a modified version of the herpes virus could offer hope for some people with advanced #Cancer.

The ICR on Twitter: "Professors Kevin Harrington and Alan Melcher (ICR +  @royalmarsdenNHS) featured earlier in a @BBCr4today segment on  #immunotherapy. In the UK you can still listen to today's live program
The ICR on Twitter: "Professors Kevin Harrington and Alan Melcher (ICR + @royalmarsdenNHS) featured earlier in a @BBCr4today segment on #immunotherapy. In the UK you can still listen to today's live program

Royal Marsden researchers named among world's most influential scientists |  The Royal Marsden
Royal Marsden researchers named among world's most influential scientists | The Royal Marsden

Stort gennembrud i kræftbehandling på vej: 'Fremtiden er her allerede' | BT  Udland - www.bt.dk
Stort gennembrud i kræftbehandling på vej: 'Fremtiden er her allerede' | BT Udland - www.bt.dk

BBC Two - Trust Me, I'm a Doctor, Series 3, Episode 3 - Could viral  immunotherapy be a revolution in cancer treatment?
BBC Two - Trust Me, I'm a Doctor, Series 3, Episode 3 - Could viral immunotherapy be a revolution in cancer treatment?

ICR Discovery Club showcases how we combine therapies to target  hard-to-treat cancers - The Institute of Cancer Research, London
ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London

The ICR on Twitter: "ICR's Professor Kevin Harrington speaks about the  @NICEcomms news about immunotherapy #nivolumab https://t.co/pRd7KUmAmR  #CancerDrugsFund https://t.co/ompikxJVHr" / Twitter
The ICR on Twitter: "ICR's Professor Kevin Harrington speaks about the @NICEcomms news about immunotherapy #nivolumab https://t.co/pRd7KUmAmR #CancerDrugsFund https://t.co/ompikxJVHr" / Twitter

High-tech radiotherapy, drug combinations and immunotherapy showcased as  future of cancer treatment - The Institute of Cancer Research, London
High-tech radiotherapy, drug combinations and immunotherapy showcased as future of cancer treatment - The Institute of Cancer Research, London

Using Viruses to Treat Cancer | Prof Kevin Harrington | #SCIPEL 2015 | SCI  - YouTube
Using Viruses to Treat Cancer | Prof Kevin Harrington | #SCIPEL 2015 | SCI - YouTube

The Institute of Cancer Research - Professor Kevin Harrington (ICR + Royal  Marsden NHS Foundation Trust) responds to today's news of the 2018 Nobel  Prize for Physiology or Medicine being awarded to
The Institute of Cancer Research - Professor Kevin Harrington (ICR + Royal Marsden NHS Foundation Trust) responds to today's news of the 2018 Nobel Prize for Physiology or Medicine being awarded to

The ICR on Twitter: "Professor Kevin Harrington explained the basic  principles of using viruses to treat cancer and talked about the  cancer-killing virus therapy, T-VEC. Find out more about how viral  immunotherapies
The ICR on Twitter: "Professor Kevin Harrington explained the basic principles of using viruses to treat cancer and talked about the cancer-killing virus therapy, T-VEC. Find out more about how viral immunotherapies